Capital Management, Llc Kol... Net Worth

The estimated Net Worth of Capital Management, Llc Kol... is at least $45.9 Milion dollars as of 24 January 2019. Capital Kol owns over 263,158 units of Wave Life Sciences stock worth over $45,873,721 and over the last 9 years Capital sold WVE stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Capital Kol WVE stock SEC Form 4 insiders trading

Capital has made over 6 trades of the Wave Life Sciences stock since 2015, according to the Form 4 filled with the SEC. Most recently Capital bought 263,158 units of WVE stock worth $10,000,004 on 24 January 2019.

The largest trade Capital's ever made was buying 2,237,130 units of Wave Life Sciences stock on 7 October 2015 worth over $24,295,232. On average, Capital trades about 427,944 units every 134 days since 2015. As of 24 January 2019 Capital still owns at least 7,775,207 units of Wave Life Sciences stock.

You can see the complete history of Capital Kol stock trades at the bottom of the page.

What's Capital Kol's mailing address?

Capital's mailing address filed with the SEC is 20 PARK PLAZA, SUITE 120020 PARK PLAZA, SUITE 1200, , BOSTONBOSTON, MAMA, 0211602116.

Insiders trading at Wave Life Sciences

Over the last 9 years, insiders at Wave Life Sciences have traded over $19,158,839 worth of Wave Life Sciences stock and bought 18,619,108 units worth $128,204,225 . The most active insiders traders include Plc Gsk, Capital Management, L.P.Ra ... a Capital Management, Llc Kol.... On average, Wave Life Sciences executives and independent directors trade stock every 43 days with the average trade being worth of $1,569,819. The most recent stock trade was executed by Paul Bolno on 21 August 2024, trading 48,366 units of WVE stock currently worth $279,555.

What does Wave Life Sciences do?

wave life sciences ltd. (nasdaq: wve) is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. given the unique versatility of its chemistry platform, wave’s pipeline spans multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded rnai.

Complete history of Capital Kol stock trades at Aclaris Therapeutics Inc, KalVista Pharmaceuticals Inc a Wave Life Sciences

Wave Life Sciences executives and stock owners

Wave Life Sciences executives and other stock owners filed with the SEC include:

• Paul Bolno,
  President, Chief Executive Officer, Director
• Christopher Francis,
  Senior Vice President - Corporate Development, Head of Emerging Areas
• Michael Panzara,
  Chief Medical Officer
• Chandra Vargeese,
  Senior Vice President, Head of Drug Discovery
• Dr. Paul B. Bolno M.B.A., M.D., MBA,
  Pres, CEO & Director
• Dr. Michael A. Panzara M.D., M.P.H., MPH,
  Chief Medical Officer and Head of Therapeutics Discovery & Devel.
• Dr. Chandra Vargeese Ph.D.,
  Chief Technology Officer
• Gregory Verdine,
  Director
• Mark Corrigan,
  Independent Director
• Amy Pott,
  Independent Director
• Heidi Wagner,
  Independent Director
• Christian Henry,
  Independent Chairman of the Board
• Peter Kolchinsky,
  Independent Director
• Ken Takanashi,
  Independent Director
• Adrian Rawcliffe,
  Independent Director
• Koji Miura,
  Independent Director
• Kenneth Rhodes,
  Senior Vice President - Therapeutics Discovery
• David Gaiero,
  Interim Chief Financial Officer
• Kate Rausch,
  Investor Relations
• Anne-Marie Li-Kwai-Cheung,
  Sr. VP of Regulatory Affairs, Compliance & Policy
• Dr. Sridhar Vaddeboina Ph.D.,
  Sr. VP of Chemistry, Manufacturing & Controls
• Jose Juves,
  Sr. VP of Corp. Affairs & Patient Advocacy
• Jonathan Rosin,
  Chief HR Officer
• Dr. Christopher Francis Ph.D.,
  Sr. VP of Corp. Devel. & Head of Emerging Areas
• Linda Rockett J.D.,
  Gen. Counsel
• Kyle B. Moran CFA,
  CFO & Principal Accounting Officer
• Chris Francis,
  See Remarks
• Plc Gsk,
  10% owner
• Keith Regnante,
  Chief Financial Officer
• Takeshi Wada,
  Director
• Ken Shin Nippon Biomedical ...,
  
• Masaharu Kagoshima Shinsang...,
  
• Roberto Guerciolini,
  See Remarks
• Masaharu Tanaka,
  Director
• Peter Kolchinsky,
  Director
• Capital Management, Llc Kol...,
  
• Mark Baldry,
  Chief Commerical Officer
• Capital Management, L.P.Ra ...,
  
• Kyle Moran,
  Chief Financial Officer
• Aik Na Tan,